Was President Trump right to extend 'most favored nation' drug pricing to every state's Medicaid program?
On September 18, 2026, President Trump announced the extension of 'most favored nation' prescription drug pricing agreements to state Medicaid programs in all 50 states, Washington, D.C., and Puerto Rico, joined by HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz.
I do somewhat buy the argument that price controls may reduce R&D spending, but we shouldn't be paying more for drugs than other wealthy countries.
If you're voting "no it was wrong," what's your actual fix for states paying wildly different prices for the same drug?